Policy | September 04, 2021
Govt revises NLEM and slashes prices of 39 drugs
At present 18 per cent of the local pharmaceutical market is under government's price control
At present 18 per cent of the local pharmaceutical market is under government's price control
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The clinical research organisation located in Hyderabad is a USFDA inspected facility
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company is eligible for 12 months exclusivity from launch
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Subscribe To Our Newsletter & Stay Updated
